AI, security, digital tools, software and products, startups, semiconductors, industrial technology, and the policy around them.
China's internet regulator registered Apple Intelligence for use on iPhones on July 15, 2026, clearing a major barrier to its release in mainland China. The service will draw on AI models from Alibaba and Baidu, but Apple has not announced a launch date.
National Taiwan University Hospital said in 2026 that it had built a federated-learning platform with partner hospitals to validate medical AI without moving their data off site. The approach limits centralized data collection, but it does not eliminate privacy, performance or accountability risks.
The US Food and Drug Administration cleared AEYE-DS for use with the handheld Optomed Aurora retinal camera on April 23, 2024. The system automatically returns a screening result, but its authorization and performance data have defined limits.
Tesla and SpaceX unveiled a US$16.8 billion first phase for their Terafab semiconductor campus in Grimes County, Texas, on August 6, 2026. The plan would bring logic, memory and packaging into one site, but neither a production date nor a detailed manufacturing roadmap is public.
The US Food and Drug Administration announced its first TEMPO participant on July 22, 2026 and now lists two manufacturers in the pilot. Their devices can enter Medicare-supported care through conditional enforcement discretion and real-world data collection, not a finding of effectiveness for the uses under review.
Samsung unveiled its eighth-generation Galaxy Z foldables on July 22, 2026, with the Galaxy Z Fold8 built around a 7.6-inch inner display. That larger workspace can reduce app switching, but buyers still carry a thicker phone and face market-specific repair costs.
TrendForce forecast conventional DRAM contract prices would rise 13 to 18 percent quarter on quarter in the third quarter of 2026, with NAND Flash up 10 to 15 percent. AI and server demand is drawing capacity away from consumer products, but retail prices still vary by market, model and inventory.
The FIDO Alliance estimated in May 2026 that five billion passkeys were in use worldwide as more services offered passwordless sign-in. Passkeys block reusable secrets from reaching phishing sites, but users must plan for device loss and cross-platform access.
Apple released iOS 26.6 on July 27, 2026, with fixes for flaws affecting components including WebKit, Wi-Fi and the operating-system kernel. Phone owners weighing an update should separate security exposure from early performance problems, then verify backups and recovery options before installing it.
Microsoft said on July 31, 2026, that it is reducing the Windows memory footprint on PCs with at least 8GB of RAM. Users can act sooner by identifying heavy processes and limiting unneeded startup, background and sync activity, without disabling security features or installing RAM cleaners.
Taiwan added 17 smart assistive products to a long-term-care rental benefit on July 1, 2026. The published list identifies products and suppliers but does not provide performance metrics or explain how each system makes decisions.
OpenAI began rolling out Health in ChatGPT to US adults on July 23, 2026, with connections to Apple Health and supported medical records. Taiwan's My Health Bank SDK instead sends selected records to third-party apps after a government review, and new SDK applications are currently paused.
Coinkite warned on July 30, 2026, that seeds created by several Coldcard models on affected firmware may be exposed because seed generation used a general-purpose pseudorandom generator. A build integration error silently routed the process away from the hardware random-number generator without stopping the firmware build.
A September 2025 paper argued that language-model training and widely used benchmarks reward guessing over acknowledging uncertainty. A 2026 health-chatbot audit found 49.6 percent of answers problematic, showing how fluent errors can reach high-stakes uses.
AI-designed drug candidates have moved into mid- and late-stage trials, but APPI News found no publicly identified US approval for a novel drug originating from an AI-led discovery program as of August 4, 2026. Early data point to faster candidate selection and stronger Phase 1 results, while later trials still impose the usual tests of safety and efficacy.
Taiwan-listed Bionime secured a local medical-device license for its iFree2 continuous glucose monitor in April 2026, but the public notice did not identify an AI forecasting feature. Abbott's Libre Assist offers such predictions in the United States, while Abbott's Taiwan product site lists an older sensor and does not advertise the feature.
Taiwan's health insurance agency said in August 2024 that it aimed to finish a cost-effectiveness review of AI diagnostic tools by the end of that year. APPI News could not find a published payment decision for the proposed CT brain-scan application as of August 3, 2026.
A 2025 laboratory study found that six wrist-worn trackers identified more than 90 percent of sleep intervals but correctly identified only 29.39 percent to 52.15 percent of wake intervals. Their movement and pulse sensors can show broad patterns, but their sleep-stage estimates do not match direct physiological measurements consistently.
